Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
You may also be interested in...
Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.
Merck’s head of clinical immunology and 2022 Rising Leader Aileen Pangan is empowering researchers to become leaders through a highly tailored and honest approach to mentorship.
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.